AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 173 filers reported holding AXSOME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $552,970 | -21.0% | 7,912 | -18.8% | 0.01% | -20.0% |
| Q2 2023 | $699,916 | +16.9% | 9,740 | +0.4% | 0.02% | +7.1% |
| Q1 2023 | $598,604 | -4.0% | 9,705 | +20.1% | 0.01% | -22.2% |
| Q4 2022 | $623,519 | +47.1% | 8,084 | -15.0% | 0.02% | +12.5% |
| Q3 2022 | $424,000 | +16.8% | 9,511 | +0.3% | 0.02% | 0.0% |
| Q2 2022 | $363,000 | -7.6% | 9,480 | -0.1% | 0.02% | +6.7% |
| Q1 2022 | $393,000 | +4.8% | 9,487 | -5.3% | 0.02% | +15.4% |
| Q4 2021 | $375,000 | +14.0% | 10,017 | -1.2% | 0.01% | 0.0% |
| Q3 2021 | $329,000 | -28.9% | 10,137 | +47.7% | 0.01% | -31.6% |
| Q2 2021 | $463,000 | +33.0% | 6,864 | +11.8% | 0.02% | +18.8% |
| Q1 2021 | $348,000 | -26.7% | 6,141 | -6.6% | 0.02% | -36.0% |
| Q4 2020 | $475,000 | +64.4% | 6,577 | +62.3% | 0.02% | +25.0% |
| Q3 2020 | $289,000 | +7125.0% | 4,053 | +2602.0% | 0.02% | – |
| Q2 2019 | $4,000 | – | 150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |